@article{d5270e1b943a44acb0969e6c473d1e89,
title = "IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer",
abstract = "This study evaluated the potential ability of MK-0646 to inhibit IGF1-mediated biological actions and cell signaling events in Type 1 and Type 2 endometrial cancer. We found that MK-0646 treatment significantly decreased IGF1R expression. In addition, pretreatment with MK-0646 decreased the IGF1-induced phosphorylation of IGF1R, AKT and ERK. Apoptosis analyses showed that MK-0646 abolished the anti-apoptotic effect of IGF1. Furthermore, MK-0646 treatment abolished the IGF1-stimulatory effect on proliferation and enhanced the cytotoxic effect of cisplatin. These findings indicate that specific inhibition of IGF1R could be a useful therapeutic approach for Type 1 and Type 2 endometrial cancer.",
keywords = "Endometrial cancer, IGF1, IGF1 receptor, MK-0646, Uterine serous carcinoma",
author = "Connie Bitelman and Rive Sarfstein and Menahem Sarig and Zohar Attias-Geva and Ami Fishman and Haim Werner and Ilan Bruchim",
note = "Funding Information: The authors wish to thank Merck, Sharp and Dohme (MSD, Israel) and the Israel Cancer Research Fund (ICRF, Montreal, Canada) for their generous support. Funding Information: This study was supported by a grant from Merck, Sharp and Dohme (MSD, Israel) to H.W., A.F., and I.B. None of the authors has received any payment or royalty from MSD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. I.B. and H.W. wish to thank the generous support of the Israel Cancer Research Fund (ICRF), Montreal, Canada. ",
year = "2013",
month = jul,
day = "10",
doi = "10.1016/j.canlet.2013.02.009",
language = "אנגלית",
volume = "335",
pages = "153--159",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",
}
